Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elitra Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Elitra Pharmaceuticals Inc. has developed a rapid and systematic method to sequence the entire genome of microbial organisms. It will identify the genes essential to the organisms' survival and use its proprietary bioinformatics platform to prioritize and validate gene targets. Alone and with partners, it will develop and commercialize novel antibiotic and antifungal drugs to inhibit the growth of major microbial pathogens, many of which are becoming resistant to current therapeutics.
Advertisement

Related Content

Where Are They Now?
Where Are They Now?
Novel Anti-Infectives

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC090174

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel